The peripheral zone of the prostate is more prone to tumor development than the transitional zone: Is the ETS family the key?

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 313-316

  Adler, David ^a   Lindstrot, Andreas ^a   Ellinger, Jörg ^a   Rogenhofer, Sebastian ^a   Buettner, Reinhard ^a   Perner, Sven ^a   Wernert, Nicolas ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

ERG; ETS; Glands; Stroma; Transcriptional regulation

Indexed keywords

ELF 3 PROTEIN; ELF 5 PROTEIN; ETV 1 PROTEIN; ETV 4 PROTEIN; ETV 5 PROTEIN; ETV 7 PROTEIN; FEV PROTEIN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LASER MICRODISSECTION; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL ZONE; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; STROMA; TRANSITIONAL ZONE; UPREGULATION;

EID: 84855685424     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.647     Document Type: Article

References (31)

1. Arora R, Koch MO, Eble JN, Ulbright TM, Li L and Cheng L: Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100: 2362-2366, 2004. (Pubitemid 38657883)
2. Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM and Ruiter DJ: Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180: 295-299, 1996. (Pubitemid 26393679)
3. DeMarzo AM, Nelson WG, Isaacs WB and Epstein JI: Pathological and molecular aspects of prostate cancer. Lancet 361: 955-964, 2003. (Pubitemid 36332115)
4. Joshua AM, Evans A, Van der Kwast T, et al: Prostatic preneoplasia and beyond. Biochim Biophys Acta 1785: 156-181, 2008.
5. McNeal JE: The zonal anatomy of the prostate. Prostate 2: 35-49, 1981.
6. McNeal JE, Redwine EA, Freiha FS and Stamey TA: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12: 897-906, 1988. (Pubitemid 19011040)
7. Guo CC, Zuo G, Cao D, Troncoso P and Czerniak BA: Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol 22: 866-871, 2009.
8. Colombo P, Patriarca C, Alfano RM, et al: Molecular disorders in transitional vs. peripheral zone prostate adenocarcinoma. Int J Cancer 94: 383-389, 2001. (Pubitemid 32906069)
9. Laczko I, Hudson DL, Freeman A, Feneley MR and Masters JR: Comparison of the zones of the human prostate with the seminal vesicle: morphology, immunohistochemistry, and cell kinetics. Prostate 62: 260-266, 2005. (Pubitemid 40129064)
10. Thiel R and Effert P: Primary adenocarcinoma of the seminal vesicles. J Urol 168: 1891-1896, 2002.
11. Van der Heul-Nieuwenhuijsen L, Hendriksen PJ, van der Kwast TH and Jenster G: Gene expression profiling of the human prostate zones. BJU Int 98: 886-897, 2006.
12. Cunha GR: Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 74: 1030-1044, 1994.
13. Cunha GR, Hayward SW and Wang YZ: Role of stroma in carcinogenesis of the prostate. Differentiation 70: 473-485, 2002. (Pubitemid 36194313)
14. Sung SY and Chung LW: Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 70: 506-521, 2002.
15. Kaminski A, Hahne JC, El Haddouti M, Florin A, Wellmann A and Wernert N: Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts. Int J Mol Med 18: 941-950, 2006.
16. He J, Pan Y, Hu J, Albarracin C, Wu Y and Dai JL: Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther 6: 76-82, 2007. (Pubitemid 46294180)
17. Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648, 2005. (Pubitemid 41528150)
18. Furusato B, Tan SH, Young D, et al: ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 13: 228-237, 2010.
19. Kumar-Sinha C, Tomlins SA and Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat Rev 8: 497-511, 2008.
20. Cai C, Hsieh CL, Omwancha J, et al: ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 21: 1835-1846, 2007. (Pubitemid 47173795)
21. Tomlins SA, Laxman B, Dhanasekaran SM, et al: Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599, 2007. (Pubitemid 47206938)
22. Carver BS, Tran J, Chen Z, et al: ETS rearrangements and prostate cancer initiation. Nature 457: E1-3, 2009.
23. Wellmann A, Wollscheid V, Lu H, et al: Analysis of microdissected prostate tissue with ProteinChip arrays: A way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med 9: 341-347, 2002.
24. Okuducu AF, Janzen V, Hahne JC, Ko Y and Wernert N: Influence of histochemical stains on quantitative gene expression analysis after laser-assisted microdissection. Int J Mol Med 11: 449-453, 2003.
25. Okuducu AF, Hahne JC, Von Deimling A and Wernert N: Laser-assisted microdissection, techniques and applications in pathology (Review). Int J Mol Med 15: 763-769, 2005.
26. Stuart RO, Wachsman W, Berry CC, et al: In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci USA 101: 615-620, 2004. (Pubitemid 38084685)
27. Watson DK, Turner DP, Scheiber MN, Findlay VJ and Watson PM: ETS transcription factor expression and conversion during prostate and breast cancer progression. Open Cancer J 3: 24-39, 2010.
28. Peter M, Couturier J, Pacquement H, et al: A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 14: 1159-1164, 1997. (Pubitemid 27141917)
29. Shaikhibrahim Z, Lindstrot A, Langer B, Buettnerand R and Wernert N: Differential expression of ETS family members in prostate cancer tissues and androgen-sensitive and -insensitive prostate cancer cell lines. Int J Mol Med 28: 89-93, 2011.
30. Sun C, Dobi A, Mohamed A, et al: TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27: 5348-5353, 2008.
31. Xing X, Wang SC, Xia W, et al: The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 6: 189-195, 2000. (Pubitemid 30082364)